Bausch Health Companies Inc.
Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
About
CEO
Mr. Thomas J. Appio
Employees
20,270
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNYS
Address
2150 St. ElzEar Boulevard West, Laval, QC H7L 4A8, Canada
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 30, 2025 | — | — | — | — |
| Feb 20, 2025 | 1.12 | — | — | — |
| Oct 31, 2024 | 1.02 | 1.13 | 0.11 | 10.78% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 5 |
| Average estimate | — | 0.83 | — | 4.42 |
| Low estimate | — | 0.72 | — | 4.20 |
| High estimate | — | 0.95 | — | 4.70 |
| Last year EPS | — | 0.59 | — | 3.75 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-2.950%
Next qtr. (Mar 2025)
41.100%
Current year
7.680%
Next year (Dec 2025)
17.690%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 8.76B | 8.12B | 8.43B | 8.03B | 8.60B |
| Cost of revenue | 2.56B | 2.36B | 2.39B | 2.25B | 2.35B |
| Gross profit | 6.20B | 5.76B | 6.04B | 5.78B | 6.25B |
| Operating expense | |||||
| Research & development | 604.00M | 530.00M | 473.00M | 484.00M | 512.00M |
| Selling general and admin | 2.92B | 2.63B | 2.62B | 2.37B | 2.55B |
| Other operating expenses | — | — | — | — | 36.00M |
| Operating income | 1.60B | 1.39B | 1.57B | 1.28B | 1.29B |
| Non operating interest income | |||||
| Income | 26.00M | 14.00M | 7.00M | 13.00M | 12.00M |
| Expense | 1.33B | 1.46B | 1.43B | 1.53B | 1.61B |
| Other income expense | -688.00M | -69.00M | -1.17B | -695.00M | -1.53B |
| Pretax income | -390.00M | -129.00M | -1.02B | -934.00M | -1.84B |
| Tax provision | 221.00M | 83.00M | -87.00M | -375.00M | -54.00M |
| Net income | -611.00M | -212.00M | -937.00M | -559.00M | -1.78B |
| Basic EPS | -1.62 | -0.62 | -2.64 | -1.58 | -5.08 |
| Diluted EPS | -1.62 | -0.62 | -2.64 | -1.58 | -5.08 |
| Basic average shares | 365.43M | 362.90M | 359.41M | 355.00M | 352.10M |
| Diluted average shares | 365.43M | 362.90M | 359.41M | 355.00M | 352.10M |
| EBITDA | 2.89B | 2.80B | 3.13B | 3.12B | 3.38B |
| Net income from continuing op. | -611.00M | -212.00M | -937.00M | -559.00M | -1.78B |
| Minority interests | 19.00M | -13.00M | -11.00M | -1.00M | -5.00M |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 27.35B | 25.69B | 29.20B | 31.20B | 33.86B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 947.00M | 564.00M | 582.00M | 605.00M | 3.24B |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 2.00B | 1.79B | 1.78B | 1.58B | 1.84B |
| Other receivables | — | — | — | — | — |
| Inventory | 1.54B | 1.09B | 993.00M | 1.09B | 1.11B |
| Prepaid assets | — | — | 720.00M | 855.00M | 779.00M |
| Restricted cash | 15.00M | 27.00M | 1.54B | 1.21B | 1.00M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 1.09B | 776.00M | 720.00M | 855.00M | 779.00M |
| Non current assets | |||||
| Properties | 84.00M | 78.00M | 73.00M | 65.00M | 56.00M |
| Land and improvements | 74.00M | 71.00M | 74.00M | 79.00M | 79.00M |
| Machinery furniture equipment | 2.05B | 1.95B | 1.68B | 1.72B | 1.61B |
| Construction in progress | 401.00M | 280.00M | 576.00M | 436.00M | 301.00M |
| Leases | 355.00M | 342.00M | 342.00M | 360.00M | 369.00M |
| Accumulated depreciation | -2.08B | -1.92B | -1.82B | -1.78B | -1.64B |
| Goodwill | 28.82B | 28.89B | 31.86B | 34.53B | 36.45B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 6.46B | 5.80B | 6.95B | 8.45B | 10.20B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 2.41B | 2.49B | 2.59B | 2.80B | 2.10B |
| Total liabilities | 27.43B | 25.43B | 29.24B | 30.59B | 32.73B |
| Current liabilities | |||||
| Accounts payable | 719.00M | 521.00M | 407.00M | 337.00M | 503.00M |
| Accrued expenses | 1.69B | 1.62B | 1.72B | 1.66B | 1.89B |
| Short term debt | 450.00M | 432.00M | — | — | 1.23B |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 47.00M | 30.00M | 98.00M | 158.00M | 196.00M |
| Pensions | 360.00M | 300.00M | 336.00M | 316.00M | 304.00M |
| Other current liabilities | 1.04B | 1.04B | 2.64B | 2.44B | 2.12B |
| Non current liabilities | |||||
| Long term debt | 21.94B | 20.33B | 22.65B | 23.93B | 24.66B |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 163.00M | 202.00M | 529.00M | 528.00M | 705.00M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.03B | 949.00M | 855.00M | 1.23B | 1.11B |
| Shareholders equity | |||||
| Common stock | 10.42B | 10.39B | 10.32B | 10.23B | 10.17B |
| Retained earnings | -9.78B | -9.19B | -8.96B | -8.01B | -7.45B |
| Other shareholders equity | -1.88B | -2.06B | -1.92B | -2.13B | -2.09B |
| Total shareholders equity | -82.00M | 260.00M | -34.00M | 605.00M | 1.14B |
| Additional paid in capital | 214.00M | 159.00M | 462.00M | 454.00M | 429.00M |
| Treasury stock | — | — | — | — | — |
| Minority interest | 940.00M | 952.00M | 72.00M | 70.00M | 73.00M |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||
| Net Income | -611.00M | -212.00M | -937.00M | -559.00M | -1.78B | -4.14B | 2.40B | -2.41B | -288.00M | 880.00M | -863.60M | -116.00M | 159.56M | -208.19M | 176.46M | 199.90M | 195.54M | 211.63M | 236.22M | 160.99M | -40.35M | 87.80M | 87.45M | -147.98M | 62.50M | 45.40M | 35.20M | 22.70M | 5.87M | 9.48M | 3.90M |
| Depreciation | 1.26B | 1.39B | 1.55B | 1.83B | 2.08B | 2.82B | 2.86B | 2.87B | 2.47B | 1.61B | 2.02B | 986.20M | 612.60M | 254.50M | 149.26M | 102.91M | 100.77M | 95.74M | 107.71M | 93.68M | 267.47M | 89.96M | 67.87M | 21.53M | 10.10M | 5.00M | 3.20M | 2.00M | 1.25M | 783,810 | 700,000 |
| Deferred Taxes | 51.00M | -176.00M | -225.00M | -475.00M | -230.00M | -144.00M | -4.39B | -236.00M | -160.00M | 4.00M | -515.90M | -319.60M | -222.96M | -55.40M | -16.00M | -90.00M | — | — | — | — | — | — | 1.45M | 3.75M | — | — | — | — | — | — | — |
| Stock-Based Compensation | 132.00M | 126.00M | 128.00M | 105.00M | 102.00M | 87.00M | 87.00M | 165.00M | 140.00M | 78.00M | 45.50M | 66.20M | 94.02M | 98.03M | 5.61M | 7.91M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 151.00M | -1.47B | 268.00M | 382.00M | 1.50B | -200.00M | -99.00M | 131.00M | 227.00M | 56.00M | 457.50M | 109.00M | 42.26M | 89.92M | 37.05M | -389,000 | 108.87M | 235.13M | 30.03M | 56.03M | — | — | — | — | — | -100,000 | — | 600,000 | 73,319 | -100,000 | 100,000 |
| Accounts Receivable | -195.00M | -57.00M | -229.00M | 170.00M | 39.00M | 216.00M | 417.00M | -34.00M | -626.00M | -572.00M | -300.60M | -175.80M | -164.58M | 25.19M | -27.00M | 27.62M | 10.06M | 4.69M | 15.58M | 28.41M | 15.93M | -93.24M | — | -35.95M | -10.00M | -10.00M | -23.10M | -4.20M | -953,149 | -2.49M | -1.00M |
| Accounts Payable | 158.00M | -75.00M | 121.00M | -471.00M | -149.00M | -121.00M | 387.00M | -144.00M | 325.00M | 318.00M | -76.50M | -8.40M | 42.07M | -52.19M | 30.77M | -6.14M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -322.00M | -198.00M | -16.00M | -77.00M | -209.00M | -5.00M | 7.00M | -164.00M | -276.00M | -193.00M | -122.70M | -80.30M | -15.15M | 4.65M | -46.69M | 13.05M | -61.78M | -14.13M | 84.63M | -43.92M | -48.80M | 27.85M | 21.31M | -5.85M | 2.10M | 5.90M | -10.10M | -27.60M | 22.29M | 926,322 | 100,000 |
| Operating Cash Flow | 628.00M | -669.00M | 662.00M | 900.00M | 1.34B | -1.49B | 1.68B | 176.00M | 1.81B | 2.19B | 639.50M | 461.30M | 547.82M | 156.51M | 309.46M | 254.86M | 353.45M | 533.06M | 474.17M | 295.20M | 194.26M | 112.37M | 178.08M | -164.50M | 64.70M | 46.20M | 5.20M | -6.50M | 28.52M | 8.59M | 3.80M |
| Investing Activities | |||||||||||||||||||||||||||||||
| Capital Expenditures | -215.00M | -218.00M | -269.00M | -302.00M | -270.00M | -157.00M | -171.00M | -235.00M | -235.00M | -292.00M | -115.30M | -107.60M | -58.52M | -16.82M | 20.88M | -22.00M | -35.09M | -40.80M | 34.32M | -25.02M | -36.92M | -61.38M | -44.44M | 4.16M | -51.50M | -3.70M | -2.70M | -6.70M | -6.97M | -1.14M | -200,000 |
| Net Intangibles | -57.00M | -50.00M | -14.00M | -7.00M | -8.00M | -78.00M | -165.00M | -56.00M | -68.00M | -179.00M | -69.60M | -73.50M | -327.44M | -84.53M | -561.83M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -1.89B | -45.00M | — | — | -180.00M | 5.00M | — | -49.00M | -15.46B | -1.10B | -5.25B | -3.49B | -2.46B | 308.98M | -761.83M | -101.92M | — | — | — | -9.32M | -25.74M | -240.58M | — | -622.15M | — | — | — | — | — | — | — |
| Purchase of Investments | -27.00M | -17.00M | -19.00M | -4.00M | -16.00M | -7.00M | -7.00M | -1.00M | -49.00M | -72.00M | -18.20M | -7.20M | -81.09M | — | -3.82M | -86.02M | -35.91M | -4.50M | -8.79M | -7.92M | -4.56M | -85.12M | -866,000 | -2.45M | -54.70M | — | — | — | — | — | — |
| Sale of Investments | 26.00M | 22.00M | 15.00M | 8.00M | 10.00M | 7.00M | 2.00M | 17.00M | 251.00M | 53.00M | 35.20M | 624.80M | 86.64M | 7.97M | 1.08M | 109.39M | 55.95M | 4.85M | 6.30M | — | — | — | — | 65.89M | — | — | — | — | — | 200,000 | — |
| Investing Cash Flow | -2.10B | -253.00M | 396.00M | -277.00M | -411.00M | -118.00M | 3.05B | -69.00M | -15.51B | 79.00M | -5.31B | -2.89B | -2.48B | 313.47M | -742.77M | -107.83M | -15.05M | -40.45M | 31.83M | -39.26M | -278.45M | -792.47M | -57.75M | -582.30M | -129.40M | -33.00M | -3.20M | -10.40M | -10.48M | -2.79M | -1.10M |
| Financing Activities | |||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 3.29B | 6.84B | 2.10B | 3.46B | 5.96B | 8.94B | 9.42B | 1.22B | 17.82B | 1.63B | 8.39B | 6.01B | 5.39B | 992.40M | 480.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -1.71B | -7.85B | -3.44B | -5.64B | -4.42B | -10.10B | -14.21B | -2.44B | -5.19B | -3.92B | -6.40B | -2.57B | -2.62B | -791.82M | -156.27M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -106.00M | -139.00M | -173.00M | -107.00M | -111.00M | -193.00M | -177.00M | -780.00M | -406.00M | -210.00M | -245.60M | -159.70M | -158.16M | -18.19M | -399,000 | -182,000 | -338,000 | -1.45M | -2.72M | 3.75M | — | — | — | 8.30M | — | — | -100,000 | — | — | -100,000 | 2.50M |
| Financing Cash Flow | 1.48B | -474.00M | -1.51B | -2.29B | 1.43B | -1.36B | -4.97B | -2.00B | 13.59B | -2.51B | 3.94B | 3.00B | 1.97B | -175.60M | 47.05M | -210.31M | -310.64M | -65.88M | -79.51M | 11.76M | 12.08M | -370.66M | 488.27M | 117.90M | 223.10M | -68.20M | 4.40M | 200,000 | 733,191 | -28,745 | 4.90M |
| Other Cash Details | |||||||||||||||||||||||||||||||
| End Cash Position | 962.00M | 591.00M | 2.12B | 1.82B | 3.24B | 723.00M | 797.00M | 542.00M | 597.00M | 323.00M | 600.30M | 916.10M | 164.11M | 394.27M | 114.46M | 317.55M | 433.64M | 834.54M | 445.28M | 34.32M | 133.26M | 56.08M | 434.89M | 125.14M | 178.10M | 78.30M | 8.30M | — | 24.34M | 2.85M | — |
| Income Tax Paid | — | — | — | — | — | — | 179.00M | — | 95.00M | 98.70M | 65.10M | 41.40M | 45.40M | 26.30M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | 1.71B | — | 1.27B | 934.00M | 652.90M | 421.00M | 247.88M | 37.72M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 760.00M | -996.00M | 1.14B | 802.00M | 1.22B | 1.27B | 1.95B | 1.80B | 1.95B | 1.84B | 857.10M | 475.50M | 254.52M | 161.84M | 353.47M | 182.33M | 305.77M | 477.16M | 434.29M | 249.07M | 245.06M | 272.72M | 239.69M | 86.65M | 29.50M | 49.90M | 1.60M | -12.30M | 24.20M | 1.43M | -2.40M |
Error: Invalid format in Holders JSON file.
Article
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.
Feb 10, 2025
Article
Contact lens maker Bausch + Lomb rules out take-private deal
Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.
Feb 6, 2025
Article
Bausch Health Provides Update on Strategic Alternatives
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.
Feb 6, 2025
